Literature DB >> 1888931

Assessment of pain after subcutaneous injection of erythropoietin in patients receiving haemodialysis.

L A Frenken1, H J van Lier, P G Gerlag, M den Hartog, R A Koene.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1888931      PMCID： PMC1670465          DOI： 10.1136/bmj.303.6797.288

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

1.  Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.

Authors:  J W Eschbach; J C Egrie; M R Downing; J K Browne; J W Adamson
Journal:  N Engl J Med       Date:  1987-01-08       Impact factor: 91.245

2.  Treatment of the anemia of progressive renal failure with recombinant human erythropoietin.

Authors:  J W Eschbach; M R Kelly; N R Haley; R I Abels; J W Adamson
Journal:  N Engl J Med       Date:  1989-07-20       Impact factor: 91.245

3.  Variations of recombinant human erythropoietin application in hemodialysis patients.

Authors:  J Bommer; W Samtleben; K M Koch; C A Baldamus; P Grützmacher; P Scigalla
Journal:  Contrib Nephrol       Date:  1989       Impact factor: 1.580

4.  Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis.

Authors:  C G Winearls; D O Oliver; M J Pippard; C Reid; M R Downing; P M Cotes
Journal:  Lancet       Date:  1986-11-22       Impact factor: 79.321
  4 in total
  8 in total

1.  Intraperitoneal erythropoietin treatment of children with chronic renal failure.

Authors:  B T Steele; A Vigneux
Journal:  Pediatr Nephrol       Date:  1995-06       Impact factor: 3.714

Review 2.  Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure.

Authors:  C J Dunn; A Markham
Journal:  Drugs       Date:  1996-02       Impact factor: 9.546

3.  Is Recormon less painful than Eprex after subcutaneous administration?

Authors:  M W Hendriks; F P Peters; P M Hooymans; T W Van de Wiel; D Janknegt; R Janknegt; J J Lohman
Journal:  Pharm Weekbl Sci       Date:  1992-04-24

Review 4.  Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients.

Authors:  C J Dunn; A J Wagstaff
Journal:  Drugs Aging       Date:  1995-08       Impact factor: 3.923

5.  Effect of lidocaine on the hematopoietic properties of recombinant human erythropoietin in the uremic rat.

Authors:  R A Kaplan; S Allen; B A Warady; U S Alon
Journal:  Pediatr Nephrol       Date:  1994-08       Impact factor: 3.714

Review 6.  Epoetin Beta: a review of its clinical use in the treatment of anaemia in patients with cancer.

Authors:  Susan M Cheer; Antona J Wagstaff
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Pharmacokinetics of recombinant human erythropoietin in children treated with continuous ambulatory peritoneal dialysis.

Authors:  R E Reddingius; C H Schröder; A M Koster; L A Monnens
Journal:  Eur J Pediatr       Date:  1994-11       Impact factor: 3.183

8.  Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.

Authors:  M C Genovese; A Covarrubias; G Leon; E Mysler; M Keiserman; R Valente; P Nash; J A Simon-Campos; W Porawska; J Box; C Legerton; E Nasonov; P Durez; R Aranda; R Pappu; I Delaet; J Teng; R Alten
Journal:  Arthritis Rheum       Date:  2011-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.